REGENXBIO Reports Q2 Profit Driven by $100M Milestone, Extends Cash Runway into Q4 2027
RGNX has more than doubled off its 52-week low of $5.455.
Summary
REGENXBIO achieved a Q2 2026 profit of $22.7 million, driven by a $100 million AbbVie milestone, and secured $107.8 million in new equity, extending its cash runway into Q4 2027. The company also confirmed plans for Q3 2026 BLA submissions for RGX-202 and RGX-121.
Key Events · Earnings and Guidance · RGNX
-
Q2 2026 Profitability
The company reported a net income of $22.7 million for Q2 2026, a significant improvement from a net loss of $70.9 million in Q2 2025. This was primarily driven by a $100 million development milestone payment from AbbVie.
-
Extended Cash Runway
With the $100 million AbbVie milestone (received July 2026) and $107.8 million in net proceeds from a July 2026 public offering, management believes its cash, cash equivalents, and marketable securities are sufficient to fund operations into the fourth quarter of 2027. This addresses previous going concern disclosures.
-
RGX-202 BLA Submission Planned
Following positive Phase III AFFINITY DUCHENNE trial data, REGENXBIO plans to initiate a Biologics License Application (BLA) submission for RGX-202 in Q3 2026 under the accelerated approval pathway, targeting potential FDA approval in H2 2027.
-
RGX-121 BLA Resubmission Aligned with FDA
After receiving a Complete Response Letter (CRL) in February 2026, the company has aligned with the FDA on next steps for potential accelerated approval of RGX-121, with a BLA resubmission planned for Q3 2026. No additional studies are required for resubmission.
Analysis · RGNX · Life Sciences
REGENXBIO reported a significant turnaround to profitability in Q2 2026, primarily due to a $100 million development milestone from AbbVie. This, combined with a recent $107.8 million equity offering, extends the company's cash runway into Q4 2027, directly addressing prior going concern doubts. The filing also confirms a clear regulatory path for key gene therapy candidates RGX-202 and RGX-121, with BLA submissions planned for Q3 2026. While cash burn remains high and litigation continues, these financial and operational updates are highly positive for the company's near-term stability and pipeline progression.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.9% of the 327 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RGNX was trading at $10.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $685.8M. The 52-week trading range was $5.46 to $16.19. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.